Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19
AB Koopmans, MH Braakman, DJ Vinkers… - Translational …, 2021 - nature.com
Extensive migration has led to the necessity of knowledge regarding the treatment of
migrants with different ethnical backgrounds. This is especially relevant for pharmacological …
migrants with different ethnical backgrounds. This is especially relevant for pharmacological …
Interethnic variation of CYP2C19 alleles,'predicted'phenotypes and 'measured'metabolic phenotypes across world populations
I Fricke-Galindo, C Céspedes-Garro… - The …, 2016 - nature.com
The present study evaluates the worldwide frequency distribution of CYP2C19 alleles and
CYP2C19 metabolic phenotypes ('predicted'from genotypes and 'measured'with a probe …
CYP2C19 metabolic phenotypes ('predicted'from genotypes and 'measured'with a probe …
Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
SA Brown, N Pereira - Journal of personalized medicine, 2018 - mdpi.com
Variability in response to antiplatelet therapy can be explained in part by
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …
Genetic polymorphisms of CYP2C19* 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute …
X Wang, C Shen, B Wang, X Huang, J Li - Gene, 2015 - Elsevier
Backgrounds and objectives Clopidogrel, an inhibitor of platelet ADP P2Y12 receptors,
plays an important role in the prevention of stent thrombosis. However, some patients do not …
plays an important role in the prevention of stent thrombosis. However, some patients do not …
The personalization of clopidogrel antiplatelet therapy: the role of integrative pharmacogenetics and pharmacometabolomics
AM Amin, L Sheau Chin… - Cardiology research …, 2017 - Wiley Online Library
Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing
percutaneous coronary intervention. However, the variable platelets reactivity response to …
percutaneous coronary intervention. However, the variable platelets reactivity response to …
Influence of Genetic and Epigenetic Factors of P2Y12 Receptor on the Safety and Efficacy of Antiplatelet Drugs
D Danielak, K Pawlak, F Główka… - … Drugs and Therapy, 2024 - Springer
Purpose P2Y12 receptor inhibitors are drugs that decrease the risk of stent thrombosis and
lower the long-term risk of non-stent-related myocardial infarction and stroke. They inhibit …
lower the long-term risk of non-stent-related myocardial infarction and stroke. They inhibit …
The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after …
Z Zhang, M Chen, L Zhang, Q Zhao - BMC Pharmacology and Toxicology, 2020 - Springer
Background Clopidogrel is an inactive prodrug, it catalyzed into its active form by
Cytochrome 450 and Paraoxonase-1 (PON-1). polymorphisms of genes encoding these …
Cytochrome 450 and Paraoxonase-1 (PON-1). polymorphisms of genes encoding these …
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A …
Clopidogrel inhibits platelet activation and aggregation by blocking the P2Y12 receptor.
Dual antiplatelet therapy with clopidogrel and aspirin is recommended treatment by current …
Dual antiplatelet therapy with clopidogrel and aspirin is recommended treatment by current …
A synergic effect between CYP2C19* 2, CYP2C19* 3 loss-of-function and CYP2C19* 17 gain-of-function alleles is associated with Clopidogrel resistance among …
H Hassani Idrissi, W Hmimech, NE Khorb… - BMC research …, 2018 - Springer
Objective The main objective of our study was to investigate the association of CYP2C19* 2
and CYP2C19* 3 loss-of-function and CYP2C19* 17 gain-of-function variants of CYP2C19 …
and CYP2C19* 3 loss-of-function and CYP2C19* 17 gain-of-function variants of CYP2C19 …
The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after …
A Giantini, IS Timan, R Dharma… - Frontiers in …, 2023 - frontiersin.org
Despite patients with acute coronary syndrome (ACS) undergoing percutaneous coronary
intervention (PCI) and receiving clopidogrel therapy, some patients still experience major …
intervention (PCI) and receiving clopidogrel therapy, some patients still experience major …